NEW YORK, Dec. 9 (GenomeWeb News) - Benitec of Queensland, Australia, yesterday said that it had settled an intellectual property dispute with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) and the Queensland Department of Primary Industries (Queensland DPI), regarding commercialization of DNA-Directed RNA interference, or ddRNAi.
Under the terms of the agreement, Benitec will focus on commercializing ddRNAi for human applications, including research models used in functional genomics, while CSIRO will commercialize non-human applications, including plants, animals, and insects. Queensland DPI will continue its ddRNAi research and will have access to both Benitec's and CSIRO's commercialization routes.
Benitec and CSIRO will share revenues generated from the commercial applications of ddRNAi, and each party will retain the majority of revenue generated from its respective application area.
Benitec was awarded its first US Patent for its ddRNAi technology in June.